ReviewScience China. Life sciences2026
The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver fat fraction negatively correlates with lumbar BMD in normal body mass index postmenopausal women: mediated by bone marrow fat.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bidirectional communication between the liver and bone profoundly influences the development and progression of both liver and bone diseases and significantly affects systemic homeostasis. Through the metabolic and immune crosstalk mediated by hepatokines, osteokines, extracellular vesicles, gut microbiota, and neuroendocrine factors, the liver-bone axis not only affects the progression from chronic liver disease to liver cancer but also modulates the balance of bone formation and resorption as well as bone marrow homeostasis. Furthermore, a dysfunctional liver-bone axis can lead to systemic complications characterized by dyslipidemia and hyperglycemia. In this review, we discuss the pathophysiological changes induced by the dysregulated liver-bone axis and elucidate the specific mediating factors and mechanisms involved. We also summarize the current efforts in translating the liver-bone axis into clinical applications, aiming to provide potential therapeutic strategies for liver and bone diseases.
Indexed as
Identifiers
42026367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.